News | August 04, 2022
Lupin Q1 FY23 consolidated loss drops to Rs. 89.08 Cr
Lupin is the 6th largest company in the Indian Pharmaceutical Market
Lupin is the 6th largest company in the Indian Pharmaceutical Market
Driven by a strong commitment to better serve its global customers in medical and consumer products, this investment represents the largest capacity expansion in Cariflex’s existing accomplishments
Sun Pharma will receive from Cassiopea the exclusive right to develop and commercialize WINLEVI in Japan, Australia, New Zealand, Brazil, Mexico and Russia.
Manish led SeQuent since 2014 and played a major role in transforming the company
H Clinical is the leader in decentralized clinical trial support and home visits in Latin America
Site has a capital investment program of ~$30 million spent or committed over the last three years to expand capabilities and improve operational efficiencies
Besides enhancing workflow operations by connecting scientists with their lab instruments and data, digitalization holds the potential to acceleratee long-term business growth
Positive opinion could expand the role of Cosentyx (secukinumab) in reducing flare risk in pediatric enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) patients in the EU
Leading this effort was Cytel’s principal research scientist and Professor of Health Research Methods at McMaster University in Canada, Dr. Edward Mills
Rodolfo brings with him a wealth of rich experience from commercial, marketing, and general management roles across several multinational companies
Subscribe To Our Newsletter & Stay Updated
